Home Featured Page 115

Featured

Latest

Video Briefing: The Psychedelics Executive Order

President Trump Signs Executive Order to Accelerate Psychedelic Research and Access

Op-Ed: Iboga, Ibogaine & 5-MeO-DMT: What gets missed when complex medicines are reduced to standard protocols

A Practitioner Statement on the Responsible Development of Ibogaine in the United States – Open Letter

Dr. Michael Alpert and Peter Alberding – ALS, Existential Distress, and Ketamine Therapy

PT397 – Vital Psychedelic Conversations

Betterlife Publishes Promising Results from a Study Titled “A Non-Hallucinogenic LSD...

BetterLife Announces Pricing of Proposed Offering of Units

Revive Therapeutics Provides Update From Type C Meeting with FDA for...

BetterLife Announces Offering of Units

PT396 – Moms on Mushrooms: Motherhood and Psychedelics Inside a Broken...

Small Pharma to Host Virtual Roundtable Event with Key Opinion Leaders...

Mind the Gap: The Importance of Gender Equity in Psychedelic Clinical...

Inside Synthesis Institute’s Implosion

Reunion Neuroscience to Participate in the Oppenheimer Annual Healthcare Conference

EDITOR PICKS

Video Briefing: The Psychedelics Executive Order

President Trump Signs Executive Order to Accelerate Psychedelic Research and Access

Op-Ed: Iboga, Ibogaine & 5-MeO-DMT: What gets missed when complex medicines...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Video Briefing: The Psychedelics Executive Order

President Trump Signs Executive Order to Accelerate Psychedelic Research and Access

Op-Ed: Iboga, Ibogaine & 5-MeO-DMT: What gets missed when complex medicines are reduced to standard protocols

A Practitioner Statement on the Responsible Development of Ibogaine in the United States – Open Letter

Dr. Michael Alpert and Peter Alberding – ALS, Existential Distress, and Ketamine Therapy

PT397 – Vital Psychedelic Conversations

Betterlife Publishes Promising Results from a Study Titled “A Non-Hallucinogenic LSD...

BetterLife Announces Pricing of Proposed Offering of Units

Revive Therapeutics Provides Update From Type C Meeting with FDA for...

BetterLife Announces Offering of Units

PT396 – Moms on Mushrooms: Motherhood and Psychedelics Inside a Broken...

Small Pharma to Host Virtual Roundtable Event with Key Opinion Leaders...

Mind the Gap: The Importance of Gender Equity in Psychedelic Clinical...

Inside Synthesis Institute’s Implosion

Reunion Neuroscience to Participate in the Oppenheimer Annual Healthcare Conference

EDITOR PICKS

Video Briefing: The Psychedelics Executive Order

President Trump Signs Executive Order to Accelerate Psychedelic Research and Access

Op-Ed: Iboga, Ibogaine & 5-MeO-DMT: What gets missed when complex medicines...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY